Boehringer Ingelheim has launched a new platform through which it will offer open access to selected preclinical molecules in order to 'unlock the full potential' of compounds no longer under development by the company.
Advanced imaging in drug discovery aims to improve the success rate of drug development as the industry continues to tackle devastating diseases such as Alzheimer’s – but no research lab can do it alone, says Charles River managing director.
Horizon Discovery and The Michael J. Fox Foundation have introduced two new preclinical models for Parkinson’s Disease research – including a first-of-its-kind model that will help researchers understand the biology behind a mutation linked to the disease.
Concept Life Sciences has acquired Aquila BioMedical, citing the CRO’s specific skill set, which will allow the company to provide services in areas “not previously accessible,” says executive chairman.